A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy

CONCLUSION: Our findings suggested that TPC combination could be a cost-saving option in patients with HER2+BC at high-risk of recurrence.PMID:37573652 | PMC:PMC10428118 | DOI:10.1016/j.breast.2023.08.005

Source: Breast - August 13, 2023 Category: Cancer & Oncology Authors: Alberto Zambelli Marina Cazzaniga Nicla La Verde Elisabetta Munzone Ippazio Cosimo Antonazzo Lorenzo Giovanni Mantovani Serena Di Cosimo Anna Mancuso Daniele Generali Paolo Angelo Cortesi Source Type: research